METTL3, an Independent Adverse Prognostic Factor for AML, Promotes the Development of AML by Modulating the PGC-1α-MAPK Pathway and PGC-1α-Antioxidant System Axis.

ABSTRACT:

Background

m⁶A represents a prevalent epigenetic modification of mammalian mRNAs. Studies have demonstrated that m⁶A RNA methylation-modifying enzymes play crucial roles in the onset and progression of AML. However, their clinical relevance remains undefined, and the mechanisms underlying their modulation of AML have yet to be elucidated.

Results

The expression levels of the m⁶A RNA-modifying enzymes METTL3, METTL14, WTAP, FTO and ALKBH5 were elevated in AML patients. METTL3-positive AML is often accompanied by DNMT3A mutations and is also an independent poor prognostic factor for AML patients. Following METTL3 knockdown, we observed a decrease in the m⁶A level of the mitochondrial oxidative stress gene PGC-1α in K562 and MV4-11 ce

SUBMITTER: Tang Y 

PROVIDER: S-EPMC11962650 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature